论文部分内容阅读
为了解ＣＤＫＮ２基因与卵巢癌发生、生物学行为和预后的关系，采用ＳＰ法免疫组织化学染色观察了该基因产物ｐ１６蛋白在卵巢癌的表达情况。发现卵巢癌中ｐ１６蛋白的阳性率低于正常卵巢、良性和交界性肿瘤（Ｐ＜０．０１）。不同组织类型和不同分化程度卵巢癌之间ｐ１６蛋白的阳性率无显著差别（Ｐ＞０．０５），Ⅰ～Ⅱ期癌的阳性率高于Ⅲ～Ⅳ期癌（Ｐ＜０．０５），ｐ１６蛋白阴性的卵巢癌患者，其累积生存率低于ｐ１６蛋白阳性者（Ｐ＜０．０１）。结果表明，ＣＤＫＮ２基因失活与卵巢癌的发生有关，ｐ１６蛋白表达缺失与卵巢癌进展和预后不良有关。
To understand the relationship between CDKN2 gene and the occurrence, biological behavior and prognosis of ovarian cancer, the expression of p16 protein in ovarian cancer was observed by SP immunohistochemical staining. The positive rate of p16 protein in ovarian cancer was lower than that in normal ovarian, benign, and borderline tumors (P<0.01). There was no significant difference in the positive rate of p16 protein between ovarian cancer tissues with different tissue types and different differentiation degrees (P>0.05). The positive rate of stage I-II cancer was higher than that of stage III-IV cancer (P<0.05). The cumulative survival rate of p16 protein negative ovarian cancer patients was lower than that of p16 protein positive patients (P<0.01). The results showed that the inactivation of CDKN2 gene was associated with the occurrence of ovarian cancer. The loss of p16 protein expression was associated with the progression and poor prognosis of ovarian cancer.